ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Role of ADME characteristics in drug discovery and their in silico evaluation:: In silico screening of chemicals for their metabolic stability

Gombar, VK; Silver, IS; Zhao, ZY
CURRENT TOPICS IN MEDICINAL CHEMISTRY2003DOI: 10.2174/1568026033452014
64被引6阅读
引用收藏
分享

摘要

Drug discovery is a long. arduous process broadly grouped into disease target identification, target validation. high-throughput identification of "hits" and "leads", lead optimization, and pre-clinical and clinical evaluation. Each area is a vast discipline ill itself. However, all but the first two stages involve, to varying degrees, the characterization of absorption, distribution, metabolism, excretion, (ADME), and toxicity (T) of the molecules being pursued as potential drug candidates. Clinical failures of about 50% of the Investigational New Drug (IND) filings are attributed to their inadequate ADMET attributes. It is, therefore, no surprise that, in the current climate of social and regulatory pressure on healthcare costs, the pharmaceutical industry is searching for any means to minimize this attrition. Building mathematical models. called ill silico screens, to reliably predict ADMET attributes solely from molecular structure is at the heart of this effort in reducing costs as well as development cycle times. This article reviews the emerging field Of 117 silico evaluation of ADME characteristics. For different approaches that have been employed it) this area, a critique of the scope and limitations of their descriptors, statistical methods, and reliability are presented. For instance, are geometry-based descriptors absolutely essential or is lower-level structure quantification equally good? What advantages, if ally, do we have for methods like artificial neural networks over the cast squares optimization methods with rigorous statistical diagnostics? Is any in silico screen worth application, let alone interpretation, if it is not adequately validated? Once deemed acceptable.. what good is all in silico screen if it cannot be made available at the workbench of drug discovery teams distributed across the globe throughout multi-national pharmaceutical companies? These are not mere discussion points, rather this article embarks on the stepwise mechanics of developing a successful in silico screen. The process is exemplified by our efforts in developing one such screen for predicting metabolic stability of chemicals in a human S9 liver homogenate assay. A real-life use of this in silico screen in a variety of discovery projects at GlaxoSmithKline is presented, highlighting successes and limitations of such applications. Finally, we project some capabilities of in silico ADME tools for greater impact and contribution to successful, efficient drug discovery.

学科与关键词

关键词
ELECTROTOPOLOGICAL STATE INDEXESMOLECULAR-SURFACE AREAORAL BIOAVAILABILITYAQUEOUS SOLUBILITYNEURAL-NETWORKSINTESTINAL-ABSORPTIONTRANSPORT PHENOMENARELATIONSHIPS QSPRSEXPERIMENTAL-DESIGNVARIABLE SELECTION
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
CURRENT TOPICS IN MEDICINAL CHEMISTRY
发表日期
2003
卷期
第 3 卷, 第 11 期
页码
1205-1225
DOI
10.2174/1568026033452014
语言
ENGLISH
成果收录
SCIE

作者

  • G

    Gombar, VK (第一作者)

  • S

    Silver, IS

查看全部 3 位作者收起作者
  • Z

    Zhao, ZY

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417